CTLA4 and neoplasm: This aptamer forms a highly stable circular structure and comprises a CTLA-4 aptamer and a PD-L1 aptamer, serving as an immune checkpoint inhibitor by concurrently blocking the CTLA-4/B7 and PD-1/PD-L1 signaling pathways to enhance the anti-tumor immune response.